Gene: UGT2B28

54490
-
UDP glucuronosyltransferase family 2 member B28
protein-coding
4q13.2
Ensembl:ENSG00000135226 MIM:606497 Vega:OTTHUMG00000129401 UniprotKB:Q9BY64
NG_029527.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.225e-1 (AD)  7.291e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR5AS10.923
OR5M100.908
KRTAP9-60.89
OR6C750.882
OR2B30.882
TXNDC80.882
OR4C50.881
KRTAP6-20.879
OR5T20.879
OR5M10.879

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TMEM221-0.284
NOG-0.268
GDF10-0.265
DBP-0.263
CDS1-0.262
B3GALT1-0.255
CYP46A1-0.253
FUT9-0.253
SLC1A4-0.246
C16orf95-0.245

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of UGT2B28 gene27153756
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of UGT2B28 mRNA21641981
D002220CarbamazepineCarbamazepine results in increased expression of UGT2B28 mRNA17112801
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of UGT2B28 mRNA23179753
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA"27188386
D010426Pentosan Sulfuric PolyesterPentosan Sulfuric Polyester results in decreased expression of UGT2B28 mRNA28973697
C031181phenanthrenephenanthrene results in increased expression of UGT2B28 mRNA19457238
D010634PhenobarbitalPhenobarbital results in decreased expression of UGT2B28 mRNA19084549
D015474IsotretinoinIsotretinoin results in decreased expression of UGT2B28 mRNA20436886
C012589trichostatin Atrichostatin A results in increased expression of UGT2B28 mRNA24935251
D014520UrethaneUrethane results in decreased expression of UGT2B28 mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of UGT2B28 mRNA23179753
D014635Valproic AcidValproic Acid results in decreased methylation of UGT2B28 gene29154799
D014635Valproic AcidValproic Acid results in increased expression of UGT2B28 mRNA23179753|2627250
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT2B28 mRNA"27188386
C111237vorinostatvorinostat results in increased expression of UGT2B28 mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0008194UDP-glycosyltransferase activity-IBA21873635  
GO:0015020glucuronosyltransferase activity-IDA11300766  
GO ID GO Term Qualifier Evidence PubMed
GO:0008202steroid metabolic process-IDA11300766  
GO:0052697xenobiotic glucuronidation-IDA11300766  
GO ID GO Term Qualifier Evidence PubMed
GO:0005640nuclear outer membrane-IDA11300766  
GO:0005783endoplasmic reticulum-IDA11300766  
GO:0005789endoplasmic reticulum membrane-IEA-  
GO:0016021integral component of membrane-IEA-  
GO:0043231intracellular membrane-bounded organelle-IBA21873635  
KEGG ID KEGG Term
hsa00040Pentose and glucuronate interconversions
hsa00053Ascorbate and aldarate metabolism
hsa00140Steroid hormone biosynthesis
hsa00500Starch and sucrose metabolism
hsa00514Other types of O-glycan biosynthesis
hsa00830Retinol metabolism
hsa00860Porphyrin and chlorophyll metabolism
hsa00980Metabolism of xenobiotics by cytochrome P450
hsa00982Drug metabolism - cytochrome P450
hsa00983Drug metabolism - other enzymes
hsa01100Metabolic pathways
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-156580Phase II - Conjugation of compoundsTAS
R-HSA-156588GlucuronidationTAS
R-HSA-211859Biological oxidationsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23575887The effect of copy number variation in the phase II detoxification genes UGT2B17 and UGT2B28 on colorectal cancer risk. (2013 Jul 1)Angstadt AYCancer